A Randomized Controlled Clinical Trial of the GLP-1 Agonist ROSE-010 in Appetite Reduction

被引：0
|
作者：
Kenny, Enda
Mansson, Maria
Samuelson, Per
Hellstrom, Per
机构：
来源：
OBESITY | 2024年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Poster-361
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [21] Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial
    van Ruiten, Charlotte C.
    ten Kulve, Jennifer S.
    van Bloemendaal, Liselotte
    Nieuwdorp, Max
    Veltman, Dick J.
    IJzerman, Richard G.
    PSYCHONEUROENDOCRINOLOGY, 2022, 137
  • [22] The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
    Sultan Linjawi
    Bruce W. Bode
    Louis B. Chaykin
    Jean-Pierre Courrèges
    Yehuda Handelsman
    Lucine M. Lehmann
    Abhishek Mishra
    Richard W. Simpson
    Diabetes Therapy, 2017, 8 : 101 - 114
  • [23] The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
    Linjawi, Sultan
    Bode, Bruce W.
    Chaykin, Louis B.
    Courreges, Jean-Pierre
    Handelsman, Yehuda
    Lehmann, Lucine M.
    Mishra, Abhishek
    Simpson, Richard W.
    DIABETES THERAPY, 2017, 8 (01) : 101 - 114
  • [24] Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
    Blonde, Lawrence
    Rosenstock, Julio
    Del Prato, Stefano
    Henry, Robert
    Shehadeh, Naim
    Frias, Juan
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Li, Chen
    Aroda, Vanita R.
    DIABETES CARE, 2019, 42 (11) : 2108 - 2116
  • [25] Profound weight reduction with GLP-1 agonist therapy: a delayed hyper-response
    McGovern, Andrew P.
    Munro, Neil
    Watters, Kenneth
    Feher, Michael
    PRACTICAL DIABETES, 2014, 31 (07) : 286 - 286A
  • [26] Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial
    Ebdrup, Bjorn H.
    Broberg, Brian V.
    Ishoy, Pelle L.
    Bak, Nikolaj
    Andersen, Ulrik B.
    Jorgensen, Niklas R.
    Holst, Jens J.
    Knop, Filip K.
    Glenthoj, Birte Y.
    DIABETES OBESITY & METABOLISM, 2018, 20 (05): : 1327 - 1328
  • [27] Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes A randomized controlled trial exploring weekly, biweekly, and monthly dosing
    Rosenstock, Julio
    Yang, Fred
    Reusch, Jane
    Stewart, Murray
    Bush, Mark
    DIABETES CARE, 2009, 32 (10) : 1880 - 1886
  • [28] The Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A Randomized Controlled Trial Exploring Weekly, Biweekly and Monthly Dosing
    Rosenstock, Julio
    Reusch, Jane E. B.
    Bush, Mark A.
    Yang, Fred
    Stewart, Murray W.
    DIABETES, 2009, 58 : A43 - A43
  • [29] A Systematic Review and Meta-Analysis of Randomized Controlled Trials in Use of GLP-1 Receptor Agonist in Type 1 Diabetes Mellitus
    Panta, Raju
    Kunwar, Sumit
    Batra, Manav
    Ghimire, Dipesh K. C.
    Mudgal, Mayuri
    Makdissi, Antoine
    Chaudhuri, Ajay
    Dandona, Paresh
    DIABETES, 2017, 66 : A308 - A308
  • [30] Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
    Mojca Jensterle
    Simona Ferjan
    Tadej Battelino
    Jernej Kovač
    Saba Battelino
    Dušan Šuput
    Andrej Vovk
    Andrej Janež
    Trials, 22
12345